Key result
Age ≥75 years in patients on warfarin undergoing PCI was associated with significantly increased in-hospital major bleeding, longer hospitalization, and higher use of bare-metal stents.
Why the study?
Does age ≥75 years increase in-hospital major bleeding and length of hospitalization in patients on warfarin undergoing percutaneous coronary intervention?
Does age ≥75 years increase in-hospital major bleeding and length of hospitalization in patients on warfarin undergoing percutaneous coronary intervention?
In patients on warfarin undergoing PCI, advanced age (≥75 years) is associated with higher rates of in-hospital major bleeding and longer hospital stays despite similar antithrombotic management.
Answers are grounded in this paper and cite their sources.
May warrant closer bleeding surveillance in elderly warfarin patients undergoing PCI; leaves open optimal age-specific strategies.
In the patients on warfarin undergoing percutaneous coronary intervention included in the prospective, multicentre, observational WAR-STENT registry, age ≥75 years was associated with a significant increase in in-hospital major bleeding, length of hospitalization, and use of bare-metal stents, with no differences in the peri-procedural management and antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Zagnoni et al. (2022) studied this question. Age ≥75 years in patients on warfarin undergoing PCI was associated with significantly increased in-hospital major bleeding, longer hospitalization, and higher use of bare-metal stents.
Synapse has enriched 10 related papers. Consider them for comparative context: